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Abstract
Introduction: Previous studies have shown that patients with diabetes mellitus appear to have a lower prevalence
of acute lung injury. We assumed that insulin prescribed to patients with diabetes has an anti-inflammatory
property and pulmonary administration of insulin might exert beneficial effects much more than intravenous
administration.
Methods: Twenty-eight mechanically ventilated rabbits underwent lung injury by saline lavage, and then the
animals were allocated into a normoglycemia group (NG), a hyperglycemia group (HG), an HG treated with
intravenous insulin (HG-VI) group or an HG treated with aerosolized insulin (HG-AI) group with continuous infusion
of different fluid solutions and treatments: normal saline, 50% glucose, 50% glucose with intravenous insulin, or
50% glucose with inhaled aerosolized insulin, respectively. After four hours of treatment, the lungs and heart were
excised en bloc, and then high-mobility group B1 concentration in bronchoalveolar lavage fluid, interleukin-8 and
toll-like receptor 4 mRNA expression in bronchoalveolar lavage fluid cells, and lung myeloperoxidase activity were
measured.
Results: Treatment with both aerosolized insulin and intravenous insulin attenuated toll-like receptor 4 mRNA
expressions in the bronchoalveolar lavage fluid cells. Interleukin-8 and toll-like receptor 4 mRNA expression was
significantly lower in the HG-AI group than in the HG-IV group. The lung myeloperoxidase activity in the normal
healthy group showed significantly lower levels compared to the NG group but not different compared to those
of the HG, HG-VI and HG-AI groups.
Conclusions: The results suggest that insulin attenuates inflammatory responses in the lungs augmented by
hyperglycemia in acute lung injury and the insulin’s efficacy may be better when administered by aerosol.
Keywords: aerosolized insulin, hyperglycemia, acute lung injury, inflammatory responses, lung, rabbit
Introduction
Sepsis or endotoxemia induces systemic inflammatory
responses manifested by increased expression and
release of proinflammatory cytokines, chemokines and
adhesion molecules. These inflammatory responses acti-
vate inflammatory and structural cells, all of which
release inflammatory mediators that elicit the typical
pathophysiological changes of acute lung injury or acute
respiratory distress syndrome (ALI/ARDS). It has been
shown that hyperglycemia is associated with adverse
outcomes, including the increased mortality of critically
ill patients [1-7]. The increased mortality may be linked
to the concurrent actions of hyperglycemia in modulat-
ing the systemic inflammatory process [8], increasing
the risk of infection [8] and exaggerating coagulation
[9]. Hyperglycemia enhances inflammatory responses
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accompanied by sepsis [10,11]. It is also known that
hyperglycemia augments lung injury induced by lipopo-
lysaccharide (LPS), as an intravenous glucose solution
has been shown to increase serum high-mobility group
B1 (HMGB1) levels and worsen pathophysiological find-
ings in a rat model of LPS-induced lung injury [12]. In
one in vitro study, hyperglycemia enhanced cytokine
production in human peripheral blood mononuclear
cells incubated with LPS [13].
Most investigations hitherto have focused on systemic
inflammatory responses caused by sepsis or endotoxemia.
The effects of hyperglycemia on established lung injury
caused by direct insults have not been investigated.
Contrary to the findings on the effects of hyperglycemia
on sepsis or endotoxemia, clinical data indicate that dia-
betes confers protective effects against the development of
ALI/ARDS [14]. In a large cohort study by Gong et al.
[15], diabetes protected against the development of ARDS
in patients at risk for ARDS in association with causes
such as sepsis, trauma, massive transfusion and aspiration.
In a prospective, multicenter study of patients with septic
shock, glucose levels on admission were higher among
patients who did not develop ALI/ARDS than among
those who did [16,17]. Multiple reasons have been pro-
posed to explain why diabetes may protect against ALI/
ARDS, including the effect of hyperglycemia on the host
response [14], but a recent cohort study concluded that
diabetes was not associated with acute lung injury but was
associated with cardiac overload [18]. Koh et al. also clari-
fied that not diabetes but therapies associated with dia-
betes protected against adverse outcome [18]. According
to one experimental study, diabetes therapies, such as
insulin, can decrease the severity of lung injury by inhibit-
ing the serum level of HMGB1 during the acute phase of
LPS-induced lung injury [19]. Insulin treatment may exert
beneficial metabolic effects beyond glucose control, as well
as non-metabolic effects. The inhalation of aerosolized
insulin is established as a rapid and safe route to reduce
plasma glucose concentrations in diabetic rabbits [20]. In
recent studies in humans, an inhaled dry powder formula-
tion of recombinant regular human insulin has also shown
favorable effects for diabetes [21,22]. Pulmonary adminis-
tration of insulin may be beneficial for the treatment of
lung injuries induced by direct insults if the patient is
hyperglycemic.
The present study was conducted to investigate the
effects of hyperglycemia on inflammatory responses in
acute lung injury induced by whole lung lavage and to
compare the effects of pulmonary or intravenous admin-
istration of insulin on ongoing inflammatory responses
in the lungs. We assumed that if insulin has an anti-
inflammatory property, pulmonary administration of
insulin might exert beneficial effects much more than
intravenous administration.
Materials and methods
Experimental protocol
All experimental protocols were reviewed and approved
by the Animal Care and Use Committee of Tokyo Med-
ical and Dental University and were performed accord-
ing to the US National Institutes of Health guidelines.
Thirty-one rabbits weighing between 3.1 and 3.3 kg
were randomly assigned to five groups: normal, healthy
control (NL group: n = 3), acute lung injury with nor-
moglycemia (NG group: n = 7), acute lung injury with
hyperglycemia (HG group: n = 7), acute lung injury with
hyperglycemia treated with intravenous insulin (HG-VI
group: n = 7) and acute lung injury with hyperglycemia
treated with aerosolized insulin (HG-AI group: n = 7).
The animals were anaesthetized with intramuscular
ketamine hydrochloride (20 mg/kg) and pentobarbital
(15 mg/kg) and placed in a supine position. After subcu-
taneous infiltration with 1% lidocaine, a midline cervical
incision was made, the animal was tracheostomized, and
the trachea was cannulated by a tracheal tube (inner dia-
meter, 3.5 mm). The normal healthy control animals
were then sacrificed with pentobarbital, and the lungs
and heart were excised en bloc. The lungs were treated
by the same procedure as the four experimental groups,
as described later. The other animals received mechanical
ventilation with a Servo Ventilator 300 (Siemens-Elema
AB, Solna, Sweden) under the following conditions: tidal
volume, 10 ml/kg; respiratory rate, 25 breaths/minute;
inspiratory:expiratory (I:E) ratio, 1:2; fraction of inspired
oxygen (FiO2), 1.0; positive end-expiratory pressure
(PEEP), 3 cmH2O. A 22-G venous catheter was intro-
duced through the jugular vein for fluid and drug infu-
sion. An arterial catheter was placed in the carotid artery
to monitor arterial pressure and sample arterial blood.
Lactated Ringer’s solution was infused intravenously at a
rate of 10 ml/kg/h throughout the study. Anesthesia was
maintained using ketamine hydrochloride at 10 mg/kg/h
and propofol at 10 mg/kg/h, and the animals were paral-
yzed with pancuronium at 0.1 mg/kg/h intravenously.
The arterial pressure was recorded on a polygraph sys-
tem (RM6000; Nihon Kohden, Tokyo, Japan). Baseline
measurements of lung mechanics and hemodynamics
were performed after stabilization, and arterial blood was
sampled for the analysis of blood glucose (Glucocard™
GT1670; Arkray Inc., Kyoto, Japan), partial pressure of
oxygen in arterial blood (PaO2), partial pressure of carbon
dioxide in the blood (PaCO2) and pH (ABL5; Radiometer
Medical ApS, Copenhagen, Denmark). Once the baseline
measurements were complete, lung lavage was performed
with warm (38°C) normal saline (60 ml) to produce lung
injury. The animals were disconnected from the ventilator
and saline was instilled directly into the lungs via the tra-
cheal tube. The animals were then ventilated under the
previous settings for 15 s, and 10 ml of bronchoalveolar
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lavage fluid (BALF) was recovered for analysis of the
HMGB1 levels and real-time polymerase chain reaction
(RT-PCR) (baseline). Ventilation was then resumed for
90 s, and the rest of the saline was recovered by gentle
suctioning. This lavage procedure was repeated every
10 minutes until the PaO2/FiO2 level was less than
150 mmHg. Control measurements were taken 60 minutes
after confirming the establishment of lung injury, then the
mode of ventilation was changed to low tidal volume with
PEEP (tidal volume, 6 ml/kg; respiratory rate, 30 to
40 breaths/minute; I/E ratio, 1:2; FiO2, 1.0; PEEP,
10 cmH2O). The HG group, HG-VI group and HG-AI
group then received a 50% glucose solution intravenously
at an initial dose of 1.3 ml/kg over 30 minutes followed by
1.3 ml/kg/h, while the animals assigned to the NG group
received an equivalent volume of normal saline. In the
HG-VI group, a dose of insulin (23 IU/kg) (Humulin® R;
Eli Lilly Japan, Kobe, Japan) was concomitantly adminis-
tered intravenously at the infusion rate of 5.1 IU/kg/h.
The HG-AI group received equivalent doses of 23 IU/kg
of aerosolized insulin through an ultrasonic nebulizer
(Misty™; ACOMA Medical Industry Co., Ltd., Tokyo,
Japan) placed in the inspiratory limb of the ventilator cir-
cuit. The nebulizer chamber was primed with the study
medication diluted in 5 ml normal saline. The diameter of
the aerosol particle was 1 to 5 μm (published data from
the company). Nebulization was accomplished in 30 min-
utes after the initiation of glucose infusion.
Arterial blood samples were obtained for blood glucose
and blood gas analyses at 60, 120, 180 and 240 minutes
after glucose or saline infusion. The arterial pressure, heart
rat, and data on pulmonary mechanics (mean airway pres-
sure [Pmean], plateau pressure [Pplateau], and minute
volume [MV]) were also recorded at each time point.
Four hours after treatment, the animals were sacrificed
by injection of a pentobarbital overdose. The lungs and
heart were excised en bloc. BALF was harvested from the
left lung with 25 ml of normal saline. The BALF and the
fluid recovered at the induction of lung injury were centri-
fuged at 3,000 rpm (885 × g) for 15 minutes at 4°C. Cell-
free supernatant was divided into several aliquots and
stored at -80°C for measurement of HMGB1 levels. Cells
were treated by TRIzol reagent (Invitrogen Co., Carlsbad,
CA, USA) and stored at -80°C for measurement of mRNA.
Measurement of BALF HMGB1
HMGB1 levels in BALF supernatant were measured using
an enzyme linked immunosorbent assay (HMGB1 ELISA
Kit II; Shino-Test Co., Sagamihara, Japan). HMGB1 was
detected according to the manufacturer’s protocols.
mRNA analysis
Total RNA extracted from BALF cells using TRIzol
reagent was treated with DNase to remove possible
traces of contaminating DNA according to the manufac-
turer’s instructions. cDNA was then synthesized from
RNA by TaqMan®Reverse Transcription Reagents
(Applied Biosystems, Foster, CA, USA) and quantitative
RT-PCR was performed. PCR was performed with speci-
fic primers and TaqMan probes with FAST qPCR Mas-
ter Mix Plus (Nippon Gene, Tokyo, Japan), and the PCR
reaction was monitored with an ABI Prism 7900HT
Sequence Detection System (Applied Biosystems). Rela-
tive mRNA expression was quantified using the 2-ΔΔCT
method [23] with TaqMan Rabbit beta actin as internal
control.
Myeloperoxidase activity assay
The myeloperoxidase (MPO) activity was measured by a
previously described method with modifications [24,25].
Homogenized lung tissues were collected in 1.5 ml
microtube, mixed with 150 μl of 50 mM potassium
phosphate buffer (pH 6.0) containing 0.5% hexadecyltri-
methylammonium bromide and 5 mM ethylenediamine-
tetraacetic acid, incubated at 60°C for 2 hours, and
centrifuged for 30 minutes at 14,000 rpm (19,279 × g) at
4°C. After 10 μl of the supernatant was added to 90 μl of
100 mM potassium phosphate buffer (pH 6.0) containing
0.167 mg/ml o-dianisidine hydrochloride and 0.0005%
hydrogen peroxide, the change in absorbance at 460 nm
(e460 = 11.3/mM/cm) [26] was followed for three-minute
periods at regular intervals (no less than 10 seconds) by a
spectrophotometer (Gene Spec V; Hitachi High-Tech
Manufacturing & Service Co., Ltd., Tokyo, Japan). The
total protein concentration was measured with a Coo-
massie (Bradford) Protein Assay Kit (Thermo Fisher
Scientific, Rockford, IL, USA) with bovine serum albumin
(Thermo Fisher Scientific) according to the manufac-
turer’s protocols. The MPO specific activity (mU/mg
protein) was calculated. One unit of MPO activity was
defined as that required to degrade 1 μmol of H2O2 per
minute at 25°C.
Histopathologic examination
The right upper lobe of the lung was inflation-fixed with
formaldehyde solution through the right main bronchus
at 20 cmH2O. For at least 48 h after fixation, the lung
was embedded in paraffin. Next, 4-μm-thick sections
were stained with hematoxylin and eosin (HE) and exam-
ined under a light microscope. Three observers blinded
to the nature of the experiment scored lung injury from
0 (no damage) to 3 (maximal damage) according to three
assessment categories: edema, alveolar congestion and
infiltration of polymorphonuclear neutrophils (PMN) in
the airspace or vessel walls. Edema and alveolar conges-
tion were defined as the presence of intraalveolar pink
staining fluid and the presence of red blood cells in the
alveolar space, respectively.
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Wet-to-dry weight ratio of the lung
Pulmonary edema was also assessed using a wet-to-dry
weight (W/D) ratio. The right lower lobe of the lung
was weighed and placed into a desiccator (Isuzu Seisa-
kusho Co., LTD, Niigata, Japan) for one week for analy-
sis of the W/D ratio.
Statistical analysis
Data values are expressed as means ± SD or medians
and interquartile ranges, as appropriate. All statistical
analyses of recorded data were performed using the
Excel statistical software package (Ekuseru-Toukei 2010;
Social Survey Research Information Co., Ltd., Tokyo,
Japan). Comparisons between before injury and after
injury were made by Wilcoxon signed-rank test for
HMGB1 concentration and PCR. MPO activity of each
treatment group was compared with that of a NL group
using the Kruskal-Wallis test, followed by the Steel’s
multiple comparisons. The other data were analyzed by
the Kruskal-Wallis test, followed by a Steel-Dwass test
for multiple comparisons. Values of P less than 0.05
were considered statistically significant.
Results
Blood gases and pulmonary mechanics
PaO2 decreased after induction of lung injury, but the
values were elevated after application of 10 cmH2O
PEEP. The PaO2 values of the HG group were
significantly lower at the end of the experiment com-
pared to those of the HG-VI and HG-AI groups (P =
0.0211, P = 0.0095, respectively) (Table 1). There were
no significant differences in Pmean, Pplateau or MV
values among the groups during the experiment.
Blood glucose
Blood glucose levels in the HG group ranged between
430 and 448 mg/dl during the experiment, whereas
those in the NG group showed normal levels (81 to 114
mg/dl). The blood glucose levels in the HG-VI and HG-
AI group were significantly lower than those in the HG
group, but they were not reduced to normal levels. The
lowest blood glucose level in the HG-VI group (162 ±
28 mg/dl)/HG-AI group (172 ± 17 mg/dl) was observed
at 180 minutes after treatment (Figure 1).
BALF analysis
Gene expressions of interleukin-8 (IL-8) in the BALF
cells rose significantly at the end of the experiment in
all groups (before lung injury vs. end of the experiment:
NG, P = 0.0180; HG, P = 0.0180; HG-VI, P = 0.0180;
HG-AI, P = 0.0180 respectively). The gene expression of
IL-8 was lower in the HG-AI group than in the HG and
HG-VI groups (HG-AI vs. HG, P = 0.0095; HG-AI vs.
HG-VI, P = 0.0211), but there was no significant differ-
ence between the HG-AI and NG groups (P =0.8960)
(Figure 2).
Table 1 Arterial blood gas and hemodynamic data
Baseline After Injury One hour after treatment End of experiment
pH NG 7.38 ± 0.04 7.35 ± 0.06 7.27 ± 0.04 7.29 ± 0.03
HG 7.39 ± 0.04 7.34 ± 0.05 7.28 ± 0.05 7.26 ± 0.05
HG-VI 7.39 ± 0.04 7.37 ± 0.06 7.30 ± 0.03 7.32 ± 0.02
HG-AI 7.39 ± 0.02 7.33 ± 0.06 7.34 ± 0.05 7.34 ± 0.05
PaCO2 (mmHg) NG 40 ± 6 46 ± 12 57 ± 7 58 ± 3
HG 39 ± 4 49 ± 11 60 ± 5 64 ± 11
HG-VI 39 ± 4 45 ± 11 47 ± 5 47 ± 6
HG-AI 38 ± 3 48 ± 5 50 ± 8 53 ± 7
PO2/FiO2 NG 620 ± 36 105 ± 25 503 ± 71** 565 ± 62**
HG 617 ± 16 74 ± 18 420 ± 124** 378 ± 118**
HG-VI 616 ± 28 77 ± 19 586 ± 68** 609 ± 55** #
HG-AI 637 ± 21 80 ± 21 588 ± 53** 637 ± 13** ##
HR (beats/minute) NG 236 ± 34 260 ± 44 254 ± 36 261 ± 42
HG 259 ± 39 271 ± 34 269 ± 38 253 ± 43
HG-VI 232 ± 49 249 ± 33 259 ± 24 255 ± 22
HG-AI 239 ± 21 256 ± 15 270 ± 20 258 ± 32
MAP (mmHg) NG 90 ± 17 106 ± 28 99 ± 23 88 ± 25
HG 85 ± 13 106 ± 24 95 ± 20 109 ± 25
HG-VI 85 ± 7 93 ± 15 71 ± 13 71 ± 18
HG-AI 90 ± 8 102 ± 7 90 ± 10 103 ± 13
NG, acute lung injury with normoglycemia group; HG, acute lung injury with hyperglycemia group; HG-VI, acute lung injury with hyperglycemia treated with
intravenous insulin group; HG-AI, acute lung injury with hyperglycemia treated with aerosolized insulin group; HR, heart rate; MAP, mean arterial pressure. All
values are mean ± SD. **P <0.01 compared with after injury; ##P <0.01, #P <0.05 compared with the HG group.
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Figure 1 Changes in blood glucose levels during the experiment. NG, acute lung injury with normoglycemia group; HG, acute lung injury
with hyperglycemia group; HG-VI, acute lung injury with hyperglycemia treated with intravenous insulin group; HG-AI, acute lung injury with
hyperglycemia treated with aerosolized insulin group; Tx, treatment. Data are mean ± SD. **P <0.01 compared with each time-point in other
groups; ##P <0.01 compared with each time-point in the HG-VI group and HG-AI group; †P <0.05 compared with the HG-VI group; ¶¶P <0.01, HG-
AI group compared with the NG group.
Figure 2 mRNA expression of Interleukin-8 in bronchoalveolar lavage fluid cells before injury and after injury. NG, acute lung injury
with normoglycemia group; HG, acute lung injury with hyperglycemia group; HG-VI, acute lung injury with hyperglycemia treated with
intravenous insulin group; HG-AI, acute lung injury with hyperglycemia treated with aerosolized insulin group; IL-8, interleukin-8. Boxes extend
from the 25th to 75th percentile; the horizontal line shows the median. Error bars show the minimum and maximum. *P <0.05 compared with
before injury; ††P <0.01 #P <0.05 compared with after injury in NG; §§P <0.01 compared with after injury in HG group; ¶P <0.05 compared with
after injury in HG-VI group.
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The gene expressions of toll-like receptor 4 (TLR4)
did not differ before and after the experiment in the NG
(P = 1.0), HG-VI (P = 0.3105) and HG-AI (P = 0.6121)
groups, but those in the HG group (P = 0.0180) were
significantly enhanced after the experiment. The TLR4
expressions were significantly lower in the HG-AI group
than in the other groups at the end of the experiment
(P = 0.0437 vs. NG, P = 0.0095 vs. HG, P = 0.0095 vs.
HG-VI, respectively) (Figure 3).
The BALF HMGB-1 levels increased at the end of the
experiment in the NG (P = 0.0180), HG (P = 0.0180),
HG-VI (P = 0.0180) and HG-AI (P = 0.0180) groups.
The BALF HMGB1 levels at the end of the experiment
of the HG-VI group are significantly lower than those of
the HG group (P = 0.0306) (Figure 4).
Myeloperoxidase activity assay
The MPO activity of the lung in the NG group was sig-
nificantly higher than those in the NL groups (P =
0.0240), but no significant differences were found
between the NL and the other groups (Figure 5).
Lung pathology
Representative microscopic images are shown in Figure 6.
Lung injury was more prominent in the HG group than in
the NG, HG-VI and HG-AI groups, when judged on the
basis of the scores for edema, alveolar congestion and infil-
tration of PMN. No difference in the degree of injury was
found between the HG-AI group and NG group, but the
degrees of edema and alveolar congestion of HG-AI group
were significantly lower than those in the HG-VI group
(Table 2).
Wet-to-dry weight ratios
The W/D weight ratios were significantly lower in the
HG-AI group than in the HG (P = 0.0241) and NG
groups (P = 0.0172). Those of the NG, HG and HG-VI
groups were not significantly different from each other
(Table 2).
Discussion
Several studies have investigated the influences of hyper-
glycemia on inflammatory response in lungs injured by
indirect insults [19,27]. We found that hyperglycemia
enhanced inflammatory responses in the acutely injured
lung and that inhaled insulin ameliorated these
responses, as shown in reduction of IL-8 and TLR4
mRNA expressions in the BALF cells, even greater than
those treated by intravenous insulin. This suggested the
preferential effects of insulin in reducing the levels of
Figure 3 mRNA expression of Toll-like receptor 4 in bronchoalveolar lavage fluid before injury and after injury. NG, acute lung injury
with normoglycemia group; HG, acute lung injury with hyperglycemia group; HG-VI, acute lung injury with hyperglycemia treated with
intravenous insulin group; HG-AI, acute lung injury with hyperglycemia treated with aerosolized insulin group; TLR4, Toll-like receptor 4. Boxes
extend from the 25th to 75th percentile; the horizontal line shows the median. Error bars show the minimum and maximum. *P <0.05 compared
before injury in the HG group; ##P <0.01 compared with after injury in the NG group; §P <0.05 compared with after injury in the HG group; †P
<0.05 compared with after injury in the NG group; ‡‡P <0.01 compared with after injury in the HG group; ¶¶P <0.01 compared with after injury
in the HG-VI group.
Fan et al. Critical Care 2013, 17:R83
http://ccforum.com/content/17/2/R83
Page 6 of 12
Figure 4 Bronchoalveolar lavage fluid high-mobility group B1 levels before injury and after injury. NG, acute lung injury with
normoglycemia group; HG, acute lung injury with hyperglycemia group; HG-VI, acute lung injury with hyperglycemia treated with intravenous
insulin group; HG-AI, acute lung injury with hyperglycemia treated with aerosolized insulin group; HMGB1, high-mobility group B 1. Boxes extend
from the 25th to 75th percentile; the horizontal line shows the median. Error bars show the minimum and maximum. *P <0.05 compared before
injury; #P <0.05 compared with after injury in the HG group.
Figure 5 Lung tissue myeloperoxidase specific activity. mU/mg protein means milliunit per mg protein of lung tissue. NL, normal healthy
control group; NG, acute lung injury with normoglycemia group; HG, acute lung injury with hyperglycemia group; HG-VI, acute lung injury with
hyperglycemia treated with intravenous insulin group; HG-AI, acute lung injury with hyperglycemia treated with aerosolized insulin group; MPO,
myeloperoxidase. Boxes extend from the 25th to 75th percentile; the horizontal line shows the median. Error bars show the minimum and
maximum. *P <0.05 compared with the NL group.
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these cytokines and insulin’s apparent anti-inflammatory
role in counterbalancing the physiologic responses to
high glucose [28]. Recently, intravenous insulin treatment
showed inhibition on the expression of nuclear factor-
kappa B (NF-B) and TLR4 in a LPS-induced lung injury
model [29], but the present results have just confirmed
an inference that insulin in an inhaled form capable of
reaching the alveoli may exert a local anti-inflammatory
effect [30].
The animals in the present study were treated with
lung protective ventilation, a gold standard therapy in
the respiratory management of ALI/ARDS. Ventilation
strategies have been known to modulate inflammatory
responses in both normal and injured lungs [31]. Our
group has investigated the effects of PEEP on the intra-
pulmonary inflammatory responses induced by whole
lung lavage using rabbits. PEEP above the lower inflec-
tion point on the pressure volume curve decreased IL-8
levels in BALF and serum from rabbits subjected to
lung injury by whole lung lavage [32]. In a later experi-
ment with the same lung injury model, low tidal volume
with 10 cmH2O PEEP or airway pressure released venti-
lation significantly reduced the HMGB1 levels in BALF
compared to conventional tidal volume with low PEEP
[33]. Contrary to our expectations, the expression of
TLR4 was concealed even after lung injury in our NG
group. We can think of two mechanisms that may
explain this concealment of TLR4. First, ventilator
Figure 6 Representative micrograph of histopathology in each experimental group (HE stain ×400). NL, normal healthy control group;
NG, acute lung injury with normoglycemia group; HG, acute lung injury with hyperglycemia group; HG-VI, acute lung injury with hyperglycemia
treated with intravenous insulin group; HG-AI, acute lung injury with hyperglycemia treated with aerosolized insulin group. Alveolar congestion,
edema and infiltration of polymorphonuclear neutrophils were more prominent in the HG group than in other groups. Alveolar congestion,
edema had lower scores in the HG-AI group compared with the HG-VI group. Those parameters showed no difference between the NG group
and the HG-AI group.
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associated lung injury was minimized in the present
study through the use of a low tidal volume with 10
cmH2O PEEP. Given the key role of TLR4 in both ven-
tilator induced lung injury [34] and bacterial infection
or sepsis [35], we speculate that the lung protective ven-
tilation might have suppressed TLR4 mRNA expression
in our NG group. Second, hyperglycemia in itself
induces the expression of TLR4 mRNA. An in vitro
experiment showed that high glucose (270 mg/dl)
induced enhanced TLR4 expression in cultured human
monocytes after six hours of treatment [36]. TLR4 initi-
ates signaling through intracellular pathways that lead to
activation of transcription factors, such as NF-B, which
in turn results in the transcription of proinflammatory
cytokine genes [35]. These findings indicate that hyper-
glycemia is associated with up-regulation of TLR4
expression and subsequent proinflammatory cytokine
expression, such as IL-8.
Even though hyperglycemia promoted the mRNA
expression of IL-8 or TLR4 and PMN aggregation, it
diminished the MPO activity in the lung tissue. MPO is a
hemoprotein abundantly expressed in PMN and is
secreted during PMN activation. MPO plays an impor-
tant role in neutrophil bactericidal action by catalyzing
chloride ion oxidation to hypochlorous acid, which can
be a potent antimicrobial agent [37]. Recent evidence
suggests that hypochlorous acid can also induce host cell
damage, particularly under inflammatory conditions, and
thereby contribute to the development of a number of
diseases, including acute lung injury [38]. The levels of
MPO activity per lung tissue protein of the HG, HG-VI
and HG-AI groups were suppressed to the level of the
NL group regardless of use of insulin in the present
study. This suggests that insulin fails to restore MPO
activity once a hyperglycemic state has been established.
Yet as the histopathology shows, the degree of PMN infil-
tration was much higher in the HG group than in the
other groups. We could not clarify how MPO activity
depression itself affects or modifies the lung injury in the
present model. Longer term studies are necessary to
discriminate immune-compromised effects from anti-
inflammatory effects.
Besides the fact that insulin down-regulates TLR4
expression that can end in an anti-inflammatory effect,
it is also known that glycogen synthase kinase (GSK)-3,
which is a key regulatory switch for the phosphatidyli-
nositol 3-kinase (PI3K)/protein kinase B (Akt) signaling
pathway, is also modulated by insulin [39,40]. GSK-3
promotes expression of a subset of genes of inflamma-
tory molecules activated by NF-B [41], while GSK-3
inhibition provides protection from inflammatory condi-
tions [42]. Insulin binds to the insulin receptor, which,
in turn, activates the PI3K pathway and this indirectly
activates Akt via phosphorylation. Akt then phosphory-
lates and inactivates several target proteins, including
GSK-3 [43]. Kidd et al. reported that a low dose of insu-
lin (0.1 IU/kg), which did not affect blood glucose levels,
inhibited inflammation during endotoxemia by activa-
tion of the PI3K/Akt pathway [44].
It is also suggested that insulin may have another favor-
able effect on lung injury. Insulin has been proved to
decrease edema formation by inducing Na/K-ATPase
translocation [45,46], and reduce accumulation of leuko-
cytes in inflammatory lesions [47]. Simultaneously, similar
to these results, our experiment also demonstrated that
the histopathologic changes and the W/D ratio were
reduced in the HG-AI group. These results may provide a
possible mechanism that explains the anti-inflammatory
activity of aerosolized insulin.
Because frequent blood glucose measurement was
required, we used a compact device for self-monitoring
in humans. This device can register values as high as
600 mg/dl, and accuracy seems acceptable unless
applied for diagnostic purposes, such as the glucose tol-
erance test. We administered a glucose dose necessary
to keep the blood glucose level above 400 mg/dl. This
target concentration of blood glucose seems somewhat
high, but it is a concentration encountered in critically
ill patients. The same blood glucose levels have been
maintained in earlier studies exploring the effects of
Table 2 Histology injury score and lung wet-to-dry ratio at the end of the experiment
NL NG HG HG-VI HG-AI
Alveolar congestion 0.11 ± 0.33 #
0.67 ± 0.48
## **
2.48 ± 0.51
## ** §§
1.71 ± 0.56
## §§ ¶¶
0.90 ± 0.30
Edema 0 ± 0 0.19 ± 0.4 ## **
2.24 ± 0.70
## ** §§
1.67 ± 0.80
§§ ¶¶
0 ± 0
Infiltration/
aggregation of neutrophils
0 ± 0 ##
0.95 ± 0.59
## **
2.33 ± 0.73
## §§
1.33 ± 0.66
## §§
1.05 ± 0.59
Wet-to-dry
ratio
NA 7.99 ± 1.16 8.37 ± 1.52 8.69 ± 2.07 * §
6.33 ± 1.00
NL, normal healthy control group; NG, acute lung injury with normoglycemia group; HG, acute lung injury with hyperglycemia group; HG-VI, acute lung injury
with hyperglycemia treated with intravenous insulin group; HG-AI, acute lung injury with hyperglycemia treated with aerosolized insulin group; NA, not available.
Values shown are mean ± SD. ##P <0.01, #P <0.05 compared with the NL group; **P <0.01, *P <0.05 compared with the NG group; §§P <0.01, §P <0.05 compared
with the HG group; ¶¶P <0.01 compared with the HG-VI group.
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hyperglycemia on inflammatory responses associated
with endotoxemia [48-50]. It should be remembered
that hyperglycemia induced by high dose glucose infu-
sion may differ from hyperglycemia due to insulin resis-
tance frequently seen in critically ill patients. Therefore,
the results of the present study should be cautiously
interpreted in patients with hyperglycemia due to insulin
resistance. However, induction of mechanical ventilation
and acute lung injury might predispose patients to stress
responses, which impaired insulin sensitivity. Inflamma-
tion is known to impair insulin sensitivity in part via the
activation of the TLR4 [51]. The dose of aerosolized
insulin chosen in the current experiment, which was
required to decrease blood glucose, was difficult to
determine, but we performed a preliminary experiment
to measure dose response curves for aerosolized insulin
from 50 IU to 80 IU to obtain blood glucose level below
200 mg/dl. We found that the minimum required dose
was 70 IU. Because the weight range of the animals was
between 3.1 and 3.3 kg, we administered 23 IU/kg of
aerosolized insulin. In the HG-IV group, an equivalent
dose of insulin was administered by continuous intrave-
nous infusion during the experimental course (4.5 h).
Although the dose was not enough to normalize the
blood glucose levels, it was enough to ameliorate local
inflammatory responses.
The hyperglycemia-induced production of proinflam-
matory cytokines may be partly explained by the
mechanisms of hyperglycemia-induced hyperosmosis.
Booth et al. [52] demonstrated that intraperitoneal
injection of 25 mmol/l D-glucose significantly
increased leukocyte rolling and adherence in the
mesenteric venules and leukocyte transmigration com-
pared with control rats injected with Krebs-Henseleit
solution. This response, however, was not elicited by
the same concentration of L-glucose, an enantiomer of
D-glucose. Hyperosmosis in itself does not appear to
be a key exaggeration of acute inflammatory responses
in the lungs.
As is often the problem with experiments using rab-
bits, the ELISA kits for measurement of most pro- and
anti-inflammatory cytokines are not commercially avail-
able at present. The increased expression of IL-8 or
TLR4 mRNA might not reflect an increased release of
inflammatory mediators and vice versa. mRNA expres-
sion might be sometimes useful, but sometimes far from
perfect, in predicting protein expression levels. It is
known that the degree of correlation between gene
expression of and protein levels varied among different
cytokines [53]. Also each protein has a very different
half-life as the result of varied protein synthesis and
degradation [54]. Further study is necessary to examine
if the mRNA expression levels are correlated with pro-
tein production and protein degradation. Nonetheless,
our previous study indicated that both BALF and serum
IL-8 protein levels were significantly elevated in the
same lung injury model and those were reduced by lung
protective strategy [32]. We, therefore, speculate that
the different levels of mRNA expression of IL-8 among
the groups reflect different concentrations in BALF IL-8
protein. The more prominent neutrophil infiltration in
the lungs in hyperglycemia may be explained by the
higher levels of IL-8 in the lungs.
Conclusions
In summary, the results suggest that aerosolized insulin
alleviates inflammatory responses augmented by hyper-
glycemia in acute lung injury.
Key messages
• Hyperglycemia augmented inflammatory responses
in the lungs in acute lung injury caused by lung lavage.
• Hyperglycemia causes greater PMN infiltration but
low MPO activities in the lung tissue.
• Inhalation of aerosolized insulin alleviates inflamma-
tory responses much more than does intravenous
administration.
• Aerosolized insulin shows effects beyond mitigating
hyperglycemia.
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